GPI pulse™ provides a multi-dimensional view of your competitors, analogs, or therapy area through detailed price, access and HTA decision data. Through intelligent integration of data sources, you can understand how payer bodies perceive price and value in their recommendations.
Better decisions and sustainable strategies through GPI pulse™
GPI pulse™ is a dynamic value, price, and access analytics platform, utilising powerful algorithms to combine multiple data streams in a way that will give you unique insight into the full market access journey.
The platform is designed to be used as part of our comprehensive solution for pricing and market access strategy, but can also be used to create efficient, robust insights as a standalone analytics tool.Schedule a demo
Open up endless opportunities to create new workflows, features, and products or integrate with your internal platforms.
We integrate P&R data in 90+ countries and 25 HTA markets – layered with regulatory, dosing schedules, policy updates, and more.
We continually invest in technology, taxonomy, and QA to ensure the best data in the business. Get in touch for a complementary sample.
Often your queries require a personal touch. Our clients love that our expert team is only an email or call away, eager to support.
We collect data from a variety of sources: regulatory, price and reimbursement, dosing schedule, legal filings, technology appraisals and many more.
We dynamically collect each data source in real time and use clever machine learning to analyze the data and turn it into standardized attributes.
We strive to keep the best data accuracy in the business. Every record goes through three stages of verification – ‘3-eyes QA’. 1. Machine algorithms. 2. Data analyst 3. Domain expert
GPI pulse™ has complete coverage of major disease areas. P&R data coverage across 90+ countries and 25 HTA markets including North America, Europe, Latin America, Asia, Africa and Oceania
Our integrated processes and machine learning algorithms produce the best data in the business, and we’ll prove it. Just get in touch, and we’ll happily provide a complementary data sample for your review.
Price and access data are constantly changing. To combat this, we collect data in real-time and mirror the local publication cycle to ensure that you have the most up-to-date data possible.
Our investment in advanced indexing and tagging provides you with data in an analysis-ready format, allowing you to drill price, access and HTA insights down to individual pack, indication or patient level.
GPI pulse™ detects patterns in historical data and events allowing you to anticipate payer decisions and prepare accordingly.
With our deep archive of historical data, you will be able to go back in time and see what your competitors were doing at any specific moment in time or understand a competitors route to reimbursement.
Automate the surveillance of movements in your therapy area and track new approvals.
GPI pulse™ has an intuitive UI that provides instant alerts on competitor activity and insights into drivers behind the change.
GPI pulse™ employs an automated competitor detector is constantly searching for new products using molecule search keywords.
If a new player gets a price or your competitor gets regulatory or reimbursement approval, you will be the first to know about it. Keep your finger on the pulse.
From an intuitive UX/UI that provides instant alerts on competitor activity and insights into drivers behind the change to the use of machine learning to identify trends and patterns, GPI pulse™ leverages state of the art technology with the goal to a consistent, aligned intelligence and insights with features to share data and collaborate with other members of the team.
Protect your strategies from market changes. With real-time alerts, you’re in the best possible position for an effective response to any scenario.
GPI pulse™ ensures you have the most up-to-date and accurate information at all times and helps you manage your response.
Complete price and access landscape information aids the process of valuing drug therapies and empowers companies to achieve optimal reimbursement for their innovation by comparing data on a like-for-like level.